After Psychedelic Therapy: Why Patients’ Social Environments Need Attention with Dr. Edward Jacobs & Ian Roullier
As psychedelic treatments move closer to broader clinical use, treatment protocols are being trimmed down in the name of cost and scale. Integration sessions in particular are being reduced, though they importantly give patients space to process the psychedelic experience and turn what they learned into lasting therapeutic change.When these sessions are cut short, how might that work fall to partners, family members, and friends instead? And how can we make sure patients are adequately supported?In this episode, we are joined by two co-authors of a recent Perspective in the Canadian Journal of Psychiatry, “As Psychedelic Treatments Get Leaner, Patients’ Social Environments Deserve Attention,” which takes up these questions.Ian Roullier is the co-founder of the Psychedelic Participant Advocacy Network (PsyPAN). Ian’s participation in clinical trials run by Imperial College (2015) and King’s College/Compass Pathways (2019) inspired his dedication to helping bring these treatments safely to all who may benefit from them. His advocacy work has included giving public talks alongside Dr. Rosalind Watts (Imperial College/ACER Integration), speaking at international conferences such as ICPR, Borealis and Breaking Convention, addressing policy makers at the European Parliament and at the European Medicines Agency and having his journey featured by Oprah, the BBC and in Michael Pollan's bestseller 'How To Change Your Mind'. Ian is also an ACER Integration sharing circle facilitator and was part of the King's College PsiDeR trial steering committee. PsyPAN works with organisations to ensure participant wellbeing is placed at the heart of their trials and treatments, feeds the participant voice into scientific research to help improve psychedelic safeguarding and fosters community and connection for people who have received psychedelic-assisted therapy.Dr Edward Jacobs is a postdoctoral fellow in psychedelic science at Johns Hopkins, and the associate director of HOPE, the Hub at Oxford for Psychedelic Ethics. Following his PhD in the ethics of psychedelic therapies, his current research spans the influence of worldview on psychedelic experiences, stakeholder perceptions of psychedelic science, and the ethics of AI in psychedelic care. Through HOPE, he has contributed to US congressional and federal inquiries on the rollout of clinical psychedelics. Learn more at https://psychedelicethics.com If you’re listening to this podcast in November 2026, you’re invited to contribute to the Psychedelic Stakeholder Survey. Go to https://psychedelicsurvey2026.com Jacobs, E., Roullier, I., Watts, R., & Wells, H. (2026). As Psychedelic Treatments Get Leaner, Patients' Social Environments Deserve Attention. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 7067437261479491. Advance online publication. https://doi.org/10.1177/07067437261479491